Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Current Deferred Revenue (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of Current Deferred Revenue data on record, last reported at $2.7 million in Q3 2025.

  • For Q3 2025, Current Deferred Revenue changed N/A year-over-year to $2.7 million; the TTM value through Sep 2025 reached $2.7 million, changed N/A, while the annual FY2024 figure was $1.8 million, 39.06% down from the prior year.
  • Current Deferred Revenue reached $2.7 million in Q3 2025 per TNXP's latest filing, down from $3.0 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $3.0 million in Q2 2025 and bottomed at $1.8 million in Q4 2024.
  • Average Current Deferred Revenue over 3 years is $2.5 million, with a median of $2.7 million recorded in 2025.
  • The widest YoY moves for Current Deferred Revenue: up 39.06% in 2024, down 39.06% in 2024.
  • A 3-year view of Current Deferred Revenue shows it stood at $3.0 million in 2023, then tumbled by 39.06% to $1.8 million in 2024, then skyrocketed by 47.03% to $2.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $2.7 million in Q3 2025, $3.0 million in Q2 2025, and $1.9 million in Q1 2025.